Mental Health With and After Cancer: Common, Often Missed, Often Untreated

When people with cancer are assessed with a full psychiatric interview, about one in six meet the criteria for depression, and between three and four in ten have some form of mood disorder. In a large Scottish study, nearly three in four people with major depression were not receiving effective treatment for it. The most serious risks are highest in the first months after diagnosis, and support thins out once treatment ends.

A cancer diagnosis arrives with a great deal at once: tests, treatment decisions, time off work, worry about money and family, and, for many, fear about what comes next. Feeling low or anxious in response is understandable, and much of it eases with time and support. But for a sizeable minority, distress becomes a clinical depression or anxiety disorder that deserves care in its own right, and the evidence shows that services in many countries still miss it. This article sets out, at population level, how common depression and anxiety are among people living with and after cancer, why the figures vary so much between studies, when after diagnosis the most serious risks are highest, and how often people get the psychological support that guidelines call for.

About one in six meet interview criteria for depression, and screening questionnaires find more

The most widely cited estimate comes from a 2011 meta-analysis that pooled only studies using psychiatric interviews, the most rigorous way to diagnose a mental disorder. Across 70 studies of 10,071 adults in oncology and haematology settings in 14 countries, 16.3% met DSM or ICD criteria for depression, 19.4% for adjustment disorder and 10.3% for an anxiety disorder. Diagnoses overlapped: 31.6% had depression or adjustment disorder, and 38.2% had any mood disorder. In palliative care (24 studies, 4,007 people in seven countries) the pooled prevalence of depression was very similar, at 16.5%. The authors found no consistent effect of age, sex or clinical setting^[1].

The figure anyone quotes depends heavily on how depression was measured. A 2014 meta-analysis of 211 studies set the methods side by side. Studies that used a structured or semi-structured diagnostic interview found a pooled prevalence of 13%. Studies that used screening questionnaires found anything from 8% to 24%, depending on the questionnaire and the cut-off score. On interview-based measures, prevalence ranged from 3% in people with lung cancer to 31% in people with cancers of the digestive tract, and it was highest during treatment (14% by interview, 27% by questionnaire)^[4]. Neither kind of figure is wrong. A questionnaire score above a threshold flags symptoms that may need a closer look; an interview applies diagnostic criteria. They answer different questions and should not be compared as if they were the same measure.

Large single-country studies show the same pattern. In Germany, a study of 4,020 adults with cancer, sampled to reflect the national mix of cancer types, screened everyone with the PHQ-9 questionnaire and then gave 2,141 of them a standardised diagnostic interview. The four-week prevalence of any mental disorder was 31.8%, including any anxiety disorder (11.5%), any adjustment disorder (11.1%) and any mood disorder (6.5%). It was highest among people with breast cancer (41.6%) and lowest among people with pancreatic cancer (20.3%)^[5]. Using the questionnaire alone, the same German study found that 24% scored in the range for depression (PHQ-9 of 10 or more), and that after adjusting for age and sex, people with cancer had 5.4 times the odds of scoring as depressed compared with a general-population sample of 5,018 people^[6].

In Scotland, routine two-stage screening in cancer clinics (a questionnaire followed by a structured diagnostic interview for major depression) covered 21,151 people between 2008 and 2011. The prevalence of major depression was 13.1% among people with lung cancer, 10.9% with gynaecological cancer, 9.3% with breast cancer, 7.0% with colorectal cancer and 5.6% with genitourinary cancer. Within each group, depression was more common among younger people and those living in more deprived areas^[2], a reminder that the social gradient described in our study of deprivation and cancer reaches into mental health too.

Much less is known about low- and middle-income countries. A 2024 meta-analysis of 32 studies from 11 African countries found pooled prevalences of 53.2% for depression and 53.3% for anxiety among people with cancer. The authors note that the included studies relied on screening questionnaires (most often the HADS) rather than diagnostic interviews, which may have overestimated prevalence. Advanced stage and having no financial support were both associated with depression symptoms^[7]. These figures are not directly comparable with the interview-based estimates above, but they point to a large and largely unmeasured need where psycho-oncology services are scarcest.

Suicide risk is raised after a cancer diagnosis, most in the first months, and it is still rare

Population studies in several countries find that people with cancer die by suicide more often than people of the same age and sex in the general population. The largest synthesis, a 2022 meta-analysis of 28 non-overlapping studies covering 22.4 million people with cancer (searched to February 2021), found a pooled standardised mortality ratio (SMR) of 1.85 (95% CI 1.55-2.20): about 85% more suicide deaths than would be expected from general-population rates^[8]. Two things matter as much as that number. First, in absolute terms these deaths are uncommon: most people with cancer, including most who go through very hard periods, do not die by suicide. Second, the raised risk is concentrated in identifiable circumstances, which means services can anticipate it and reach people when it is highest.

The same meta-analysis shows where the risk sits. The pooled SMR was 3.03 within the first year after diagnosis and 1.39 later than that; 3.53 for cancers with a poor prognosis (five-year relative survival below 50%) against 1.50 for those with a good prognosis (above 90%); and 3.12 for late-stage against 1.50 for early-stage disease. By region, pooled SMRs were 1.51 in European studies, 1.63 in Australian, 1.97 in Asian and 2.77 in US studies. Heterogeneity between studies was very high, so these are best read as broad patterns rather than precise national rates^[8].

National registry studies fill in the detail. In England, a study linking cancer registrations for 4,722,099 adults diagnosed between 1995 and 2015 to death records (followed to August 2017) counted 2,491 deaths recorded as suicide or given an open verdict: 0.08% of all deaths in the cohort. The overall SMR was 1.20 (95% CI 1.16-1.25), equivalent to 0.19 extra deaths per 10,000 person-years. The SMR was 2.74 in the first six months after diagnosis, and was highest for mesothelioma (4.51) and pancreatic cancer (3.89), followed by oesophageal, lung and stomach cancers. The authors called these potentially preventable deaths and pointed to a need for better psychological support for everyone with cancer, with attention to modifiable factors such as pain^[9].

In Sweden, a cohort of 6,073,240 people followed from 1991 to 2006 found that, compared with people without cancer, the relative risk of suicide was 12.6 in the first week after a cancer diagnosis and 3.1 across the first year, falling quickly over that year. Even in that first week, the absolute rate was 2.50 per 1,000 person-years (29 deaths)^[10]. In Japan, the Osaka Cancer Registry (623,995 people diagnosed 1985-2013, followed for up to 10 years) found SMRs of 1.66 for men and 1.65 for women, rising to 2.54 for men and 1.87 for women with poor-prognosis cancers (defined there as five-year relative survival below 40%)^[11]. A US analysis of the SEER registries covering 1973 to 2014 reported a much higher overall SMR of 4.44 (95% CI 4.33-4.55) among 8,651,569 people with cancer^[12]. That figure is an outlier: it is well above the pooled US estimate of 2.77 in the meta-analysis above, and the authors later published a correction adding detail on how the SEER registries differ and how the standardised mortality figures were calculated. Across all of these studies, the differences reflect different countries, periods, follow-up, comparison populations and ways of recording deaths, so the estimates should not be read as a ranking or a trend.

What links these studies is timing and circumstance: risk is highest soon after diagnosis and with cancers that carry a harder outlook. Nothing in these data means that a cancer diagnosis leads to suicide. They mean that the period around diagnosis is when emotional support, symptom control and a clear route to mental health care matter most, and when services should be most alert.

Most depression goes untreated, and support after treatment is patchy

Recognising depression is only useful if care follows. In the Scottish screening programme, 1,130 of the 1,538 people with major depression who had complete treatment data (73%) were not receiving potentially effective treatment for it. The authors concluded that major depression is common in people attending cancer clinics and that most of it goes untreated^[2]. The European Society for Medical Oncology's 2023 guideline makes the same point more broadly: cases are rarely identified by surgeons or oncologists and are seldom referred to specialist psychiatry or psycho-oncology services^[13].

England's National Cancer Patient Experience Survey gives a regular view of how people experience emotional support. In the 2025 survey (64,268 respondents, a 48% response rate, all discharged from NHS trusts after cancer treatment in April to June 2025):

• 65.9% of those who had stayed overnight in hospital said they could always talk to hospital staff about their worries and fears if they needed to, unchanged from 2024;
• 79.7% of those treated as outpatients or day cases said the same;
• among people who needed it, only 32.9% said they could definitely get emotional support at home from community or voluntary services once treatment had finished, a figure that has stayed between about 31% and 34% since 2021^[3].

These are measures of experience, not of mental health need or of treatment received, and they cover one country's health service. But they describe a common shape: support is most available during active hospital treatment and thins out afterwards, at the point where many people are adjusting to life after cancer, living with fear of recurrence or the long-term effects of treatment.

Partners and family members carry their own strain, and many of the same gaps in support apply to them; that evidence is covered in our study of carers and families.

What the evidence asks of us

The evidence on what helps is reasonably consistent. The American Society of Clinical Oncology's 2023 guideline update, based on a systematic review of evidence published from 2013 to 2021, found that psychological, educational and psychosocial interventions improved depression and anxiety in adults after cancer, while evidence for medication was inconsistent. It recommends a stepped-care model (the most effective, least resource-intensive option matched to the severity of symptoms) and that all people treated for cancer are offered education about depression and anxiety. It also flagged the lack of people from minoritised groups in the research^[14]. ESMO recommends that all people with cancer are regularly screened and assessed for anxiety and depression in all phases of illness, using validated tools, and that anyone identified as a possible case is referred for a fuller specialist assessment, since screening alone is only a first step^[13].

Read together with the prevalence and suicide data, this points to a short list of things services, commissioners and funders can act on:

• Make screening lead somewhere. Routine distress and depression screening is widely recommended, but the Scottish data show that identification without a treatment pathway leaves most depression untreated. Every screening programme needs a funded route to assessment and psychological care.
• Concentrate support where the risk is. In the pooled evidence, the first year after diagnosis, cancers with a poor prognosis and late-stage disease carry the highest suicide risk, and national studies in England and Sweden put the peak in the first weeks and months. Psycho-oncology capacity, symptom control and clear contact routes should be planned around those periods, not left to chance.
• Keep support going after treatment ends. In England only about a third of people who needed emotional support after treatment could definitely get it in the community, and that figure has moved by only about one percentage point since 2021. Community and voluntary services need sustainable funding and clear links with hospital teams.
• Close the evidence gap outside high-income countries. Questionnaire-based studies from Africa suggest high levels of distress, but interview-based prevalence data, and services, are scarce. Global cancer plans should count mental health care as part of cancer care, and research funders should support studies that measure it rigorously in more settings.
• Look at who is missed. Depression was more common among younger people and those in deprived areas in Scotland, and minoritised groups are under-represented in intervention trials. Monitoring access by deprivation, ethnicity and age would show whether support reaches the people who need it most.

More on related evidence is collected in the cancer research library.

Language: this piece says "people with cancer" and "people living with and after cancer", and describes the illness and its treatment plainly, without combat metaphors. Clinical terms such as "stage", "prevalence" and "relative survival" are used in the sense the cited source defines them.

Why we're publishing this

Mental health is part of cancer care, not an extra. Charities, support groups and hospices often see the gap between what guidelines recommend and what people actually receive long before it shows up in official statistics. We have brought the population evidence together in one place so that they can make that case with figures they can cite: how common depression and anxiety are, when risk is highest, and how far current support falls short of what is recommended. The shortfall described here lies in services, not in the people who need them.

How to read this data

Prevalence figures come in two kinds. Interview-based figures apply formal diagnostic criteria (DSM or ICD) and are the stricter measure; questionnaire-based figures (such as the HADS, PHQ-9 or CES-D) count people scoring above a threshold for symptoms and usually give higher numbers. We name the measure each time, and figures from different measures should not be compared directly. Most interview-based evidence comes from Europe, North America and Australia; data from low- and middle-income countries are mostly from questionnaires.

Suicide figures are mostly standardised mortality ratios: observed deaths divided by the number expected if people with cancer had the same rates as the general population of the same age and sex (and, in some studies, period). An SMR of 1.85 means 85% more deaths than expected; it is a relative measure and says nothing on its own about how common such deaths are, which is low. Studies differ in country, period, length of follow-up and how deaths are recorded (the English study included open inquest verdicts), so their SMRs are not directly comparable. Pooled estimates from meta-analyses carry very high heterogeneity. Patient-experience survey results describe what respondents reported in one health system and are not measures of need or treatment. None of these figures can predict anything about an individual.

Use this data

Free to cite with attribution to Better Health For Everyone. Charities, campaigners and journalists are welcome to reuse these figures and charts. For the underlying figures as a spreadsheet, get in touch.

Important: This article summarises published research for general information. It is not medical advice and cannot be used to diagnose, treat or predict anything about an individual. If you have concerns about your own or someone else's health, please speak to a qualified health professional.

Sources

1. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncology, 2011. europepmc.org/article/MED/21251875
2. Walker J, Hansen CH, Martin P, Symeonides S, Ramessur R, Murray G, Sharpe M. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry, 2014. europepmc.org/article/MED/26360998
3. NHS England and Picker Institute Europe. National Cancer Patient Experience Survey 2025: national quantitative report. NCPES, 2026. ncpes.co.uk/wp-content/uploads/2026/07/1.1-NCPES25_national-quantitative-report_Final.pdf
4. Krebber AM, Buffart LM, Kleijn G, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psycho-Oncology, 2014. europepmc.org/article/MED/24105788
5. Mehnert A, Brähler E, Faller H, et al. Four-week prevalence of mental disorders in patients with cancer across major tumor entities. Journal of Clinical Oncology, 2014. europepmc.org/article/MED/25287821
6. Hartung TJ, Brähler E, Faller H, et al. The risk of being depressed is significantly higher in cancer patients than in the general population: prevalence and severity of depressive symptoms across major cancer types. European Journal of Cancer, 2017. europepmc.org/article/MED/28024266
7. Nakie G, Melkam M, Takelle GM, et al. Depression, anxiety and associated factors among cancer patients in Africa: a systematic review and meta-analysis study. BMC Psychiatry, 2024. europepmc.org/article/PMC/PMC11668085
8. Heinrich M, Hofmann L, Baurecht H, Kreuzer PM, Knüttel H, Leitzmann MF, Seliger C. Suicide risk and mortality among patients with cancer. Nature Medicine, 2022. europepmc.org/article/MED/35347279 (full text: epub.uni-regensburg.de/52193)
9. Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry, 2019. europepmc.org/article/MED/30476945
10. Fang F, Fall K, Mittleman MA, Sparén P, Ye W, Adami HO, Valdimarsdóttir U. Suicide and cardiovascular death after a cancer diagnosis. New England Journal of Medicine, 2012. europepmc.org/article/MED/22475594
11. Kitagawa S, Sobue T, Zha L, Morishima T, Ohno Y, Miyashiro I. Suicide risk among patients with cancer by sex in Japan: a population-based study. Journal of Epidemiology, 2024. europepmc.org/article/MED/38462529
12. Zaorsky NG, Zhang Y, Tuanquin L, Bluethmann SM, Park HS, Chinchilli VM. Suicide among cancer patients. Nature Communications, 2019 (author correction 2020). europepmc.org/article/MED/30643135
13. Grassi L, Caruso R, Riba MB, et al. Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline. ESMO Open, 2023. europepmc.org/article/PMC/PMC10163167
14. Andersen BL, Lacchetti C, Ashing K, et al. Management of anxiety and depression in adult survivors of cancer: ASCO guideline update. Journal of Clinical Oncology, 2023. europepmc.org/article/MED/37075262